Compare ABRDN Physical Gold Shares ETF (SGOL) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ABRDN Physical Gold Shares ETF vs Sanofi SA — how do they compare? ABRDN Physical Gold Shares ETF trades at $41.95, while Sanofi SA trades at $43.62 (market cap $104.30B). The key difference: Sanofi SA pays a 5.55% dividend while ABRDN Physical Gold Shares ETF pays none, and ABRDN Physical Gold Shares ETF is trading nearer its 52-week high, Sanofi SA nearer its low. Which is the better fit depends on your goals.
| SGOL | SNY | |
|---|---|---|
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $51.41 | $52.34 |
52-Week Low | $31.61 | $41.33 |
Market Cap | — | $104.30B |
Enterprise Value | — | $124.19B |
Dividend Yield | — | 5.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SGOL, a US-listed gold ETF, trades at $41.91, up 0.26% today, with a bullish technical signal from moving averages but bearish oscillators. Recent news highlights gold's strength amid cooling US inflation and central bank demand, with spot gold reaching $4,438/oz on August 12, 2026. The ETF lacks fundamental ratios like P/E and P/B, as it tracks physical gold, not a company with earnings.
The outlook for SGOL is positive, driven by gold's safe-haven appeal and supportive macroeconomic factors, but risks include Fed policy shifts and gold price volatility. Analyst sentiment is mixed, with technical indicators suggesting caution near overbought levels.
SNY trades at $43.54, up 0.14% today, with a neutral technical signal and bullish moving averages. Recent Q2 2026 earnings beat expectations, with EPS of $1.21 versus $1.10 expected, driven by strong Dupixent sales. The company raised its 2026 outlook, projecting ~10% sales growth. Financial health is solid with a P/E of 23.27 and robust operating cash flow of $10.75B in 2025, though net cash flow was minimal at $49M.
Outlook is cautiously optimistic with growth catalysts from Dupixent and new drug approvals, but risks include pipeline setbacks and competitive pressures. Analysts are mixed, with 44% buy ratings, highlighting potential upside to fair value estimates around $57, while debt levels and regulatory scrutiny pose challenges for sustained shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ABRDN Physical Gold Shares ETF
SGOL is an ETF that is designed to track the performance of the price of gold bullion. The fund is backed by physical gold held in secured vaults, which is allocated to the ETF's custodian account. By providing direct ownership of gold without the need for physical storage or insurance, SGOL offers investors a convenient and cost-effective way to gain exposure to the gold market.
Read more on SGOL →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
